Feedback / Questions
migaldendranib subcutaneous (D-4517.2 SC) - Ashvattha Therap
https://www.globenewswire.com/news-release/2025/06/10/3096597/0/en/ashvattha-therapeutics-to-present-phase-2-dme-and-wet-amd-data-at-clinical-trials-at-the-summit-and-maculart.html
Jun 10, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next